12 Health Care Stocks Moving In Thursday's After-Market Session
Portfolio Pulse from Benzinga Insights
In Thursday's after-market session, several healthcare stocks experienced significant movements. Gainers included cbdMD (YCBD), CEL-SCI (CVM), DermTech (DMTK), China Pharma Holding (CPHI), Accuray (ARAY), and Yield10 Bioscience (YTEN), with increases ranging from 5.08% to 16.5%. Losers comprised Cingulate (CING), Microbot Medical (MBOT), T2 Biosystems (TTOO), SenesTech (SNES), NKGen Biotech (NKGN), and AquaBounty Techs (AQB), with declines between 6.15% and 14.9%.
December 28, 2023 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI shares rose 8.7% to $3.09, with a market cap of $154.2 million.
The rise in CEL-SCI's stock price could indicate positive investor sentiment, potentially leading to further short-term gains.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
DermTech's stock increased by 7.38% to $1.89, with a market cap of $64.7 million.
DermTech's after-market rise may suggest investor confidence, potentially translating into short-term stock appreciation.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
cbdMD shares surged 16.5% to $0.92 after their Q4 earnings released 4 days ago, with a market cap of $2.7 million.
The significant after-market increase is likely due to a positive reception of their Q4 earnings report, which could lead to continued short-term bullish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Cingulate's shares dropped 14.9% to $8.33, with a market cap of $7.8 million.
The substantial decline in Cingulate's stock price suggests negative market sentiment, which could lead to further short-term depreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Microbot Medical shares fell 9.27% to $1.86, with a market cap of $21.7 million.
The after-market decline for Microbot Medical could reflect investor concerns, potentially leading to further short-term stock price erosion.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
T2 Biosystems shares decreased by 8.06% to $6.85, with a market cap of $27.7 million.
The drop in T2 Biosystems' stock price could be a sign of investor skepticism, possibly leading to a short-term negative trend.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80